RMTG Subsidiary CELLGENIC Introduces Peptide Pen Product Line at Cancún Global Summit

Pre-Loaded Synergistic Peptide Formulations Add New Revenue Stream Through Physician Distribution Network Spanning 30+ Countries

LAS VEGAS, NEVADA / ACCESS Newswire / November 18, 2025 / Regenerative Medical Technologies Group, Inc. (OTC:RMTG), a global leader in regenerative medicine solutions, today announced the successful introduction of its CELLGENIC Peptide Pen product line, officially presented during the ISSCA Global Summit held in Cancún. The new line represents an important step toward simplifying and modernizing peptide therapy within the field of regenerative and longevity medicine, while creating additional revenue opportunities through RMTG's established physician network.

Product Innovation and Revenue Potential:

The CELLGENIC Peptide Pen series was designed to offer physicians a more practical approach to peptide therapy. Each pre-loaded device contains synergistic peptide formulations that support various clinical goals such as recovery, immune balance, metabolic optimization, and overall wellness. By integrating multiple compounds into a single, ready-to-use pen, the product streamlines physician protocols while maintaining consistency and ease of use.

Foto: Accesswire

Strategic Product Launch:

• Revenue Generation: Peptide Pen line adds new product category to CELLGENIC's portfolio, distributed through RMTG's global network spanning 30+ countries

• Market Positioning: Pre-loaded synergistic formulations address growing demand for convenient peptide therapy solutions in regenerative and longevity medicine

• Distribution Advantage: Exclusive sales to licensed physicians through established RMTG affiliate network, including recent Brazil, Dominican Republic, and northern Argentina/Paraguay partnerships

• Summit Launch Platform: Global Summit presentation generated immediate physician interest and orders from international attendees representing 30+ countries

• Product Line Expansion: Peptide Pens complement existing CELLGENIC portfolio including exosomes, MSCs, and platelet-rich plasma kits, increasing average order value

• Educational Integration: ISSCA training programs incorporate peptide therapy protocols, driving product adoption through certification workshops and physician education

"We are thrilled with GSCG's launch of CELLGENIC's innovative Peptide Pen product line, which represents a groundbreaking advancement in regenerative medicine," said David Christensen, CEO of RMTG. "These pens, with their amazing premix stacked solutions, seamlessly combine synergistic peptides to deliver targeted support for recovery, immune balance, and metabolic optimization-all in a convenient, ready-to-use pen device. This is a testament to our commitment at RMTG to pushing the boundaries of personalized and performance-based therapies, empowering physicians worldwide to achieve exceptional patient outcomes."